Exclusive Summary

• Potential Best-in-Class Efficacy: In vitro reporter cell assays demonstrate that UB340 has significantly higher relative biological activity (1.32) compared to the Phase III benchmark competitor Tulisokibart/PRA023 (0.45).
• Superior Target Affinity: UB340 exhibits extremely high affinity for human TL1A (KD=4.10E-12 M), suggesting potential for lower dosing or extended intervals.
• Validated Mechanism & In Vivo Potency: TL1A is a clinically validated, high-value target in IBD; UB340 showed significant efficacy in DSS-induced UC rat models, improving colon length and stool consistency comparable to positive controls.
• Excellent Developability (CMC): The molecule demonstrates robust stability under accelerated heat stress and freeze-thaw cycles, with low oxidation and isomerization profiles favorable for manufacturing.

Asset Materials

Contact Us for Full Materials